First-in-Class: Recombinant Human Albumin Injection (Oryza Sativa) Approved by China NMPA

Healthgen’s “Recombinant Human Albumin Injection(Oryza Sativa)” was approved by the China’s National Medical Products Administration (NMPA)on 18 July, 2025.

Drug Name: Recombinant Human Albumin Injection (Oryza Sativa)

Drug Approval No.: National Drug Approval No.S20250039

Indications: Hypoproteinemia

Packing: 10g(20%,50mL)